“We are very pleased that the FDA has approved the heart failure label extension of Injectafer®, and congratulate our partner on this milestone”, said Hervé Gisserot, General Manager of CSL Vifor. “Every second patient with chronic heart failure suffers from iron deficiency, with a significant number of patients either not being diagnosed or inadequately treated for iron deficiency. We are confident that Injectafer® can make a meaningful contribution to achieve key therapeutic goals in the treatment of these patients.”
Article and further references here: LINK
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$247.45 |
Change
-3.210(1.28%) |
Mkt cap ! $119.8B | |||
| Open | High | Low | Value | Volume |
| $250.60 | $251.00 | $245.46 | $183.9M | 744.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8 | $247.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $247.45 | 145 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |